Phase 3 trial finds ensitrelvir does not enhance recovery in hospitalized adults with COVID-19, suggesting limited efficacy.
Ensitrelvir treatment did not improve clinical recovery in addition to SOC for adults hospitalized for COVID-19. The lower illness severity in the Omicron era compared to earlier periods in the COVID-19 pandemic, and high use of remdesivir and corticosteroids, may have contributed to the lack of clinical benefit.
No takes yet. Share an insight, caveat, or question.
Baker et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: